Although there are several clinical and molecular factors known to be prognostic factors for high-grade glioma, including methylation of O-6-methylguanine-DNA methyltransferase (MGMT) promoter, age, involvement of the subventricular zone (SVZ), extent of resection, and sex [2], most patients are treated with a uniform adjuvant treatment approach (i.e., one-size-fits-all). The gene discussed is MGMT; the disease is central nervous system cancer.